Compare Microsoft (MSFT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Zoetis Inc — how do they compare? Microsoft trades at $492.02 (market cap $3.67T), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Microsoft is far larger — about 120.7× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| MSFT | ZTS | |
|---|---|---|
Market Cap | $3.67T | $30.40B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $150.61 |
52-Week Low | $352.83 | $71.91 |
Enterprise Value | $3.65T | $37.96B |
Dividend Yield | 0.74% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $493.95, down 1.15% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 surpassing expectations of $4.24. Revenue growth remains solid, reaching $281.72 billion in 2025, while profitability metrics like a 40.31% net income margin and 34.04% ROE highlight operational efficiency. Analyst sentiment is overwhelmingly positive, with an 80.49% buy rating and a consensus price target of $560.43.
The outlook for MSFT is favorable, driven by AI leadership and cloud momentum, though risks include rising capital expenditures and competitive pressures. Earnings growth and Azure expansion are key catalysts for upside, while macroeconomic volatility and geopolitical tensions pose near-term headwinds. The stock's valuation at a P/E of 27.52 appears reasonable given its growth trajectory, supporting a bullish investment case for long-term holders.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
